- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06792877
Mindfulness for Cognition in Early-stage Alzheimer's Disease
Mechanisms of Mindfulness for Cognition in Early-Stage Alzheimer's Disease
The goal of this clinical trial is to learn if mindfulness meditation can improve outcomes in older adults with and without cognitive impairment. The main questions it aims to answer are:
- How does mindfulness impact thinking and memory?
- How does mindfulness influence brain function and structure?
- How does mindfulness affect daily function and quality of life?
Researchers will compare all outcomes to one other groups. In one group, individuals will participate in a mindfulness class intervention; in the other group, individuals will not engage in any active interventions immediately, but will be placed on a waitlist for the mindfulness intervention. Researchers will compare all outcomes between the groups groups to determine whether the mindfulness interventions leads to greater improvement compared to no intervention (waitlist group).
Participants will:
- Be randomly assigned to participate in the mindfulness intervention, or no immediate intervention (waitlist)
- Complete paper-and-pencil cognitive testing, surveys, computerized tasks, and neuroimaging measures (EEG and MRI) before and after the intervention
Outcomes will be assess at baseline, 2 months, 4 months and 6 months.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Katherine W Turk, MD
- Phone Number: 8573645429
- Email: ctcnbrainlab@gmail.com
Study Contact Backup
- Name: Kathy Y Xie, PhD
- Phone Number: 8572300905
- Email: ctcnbrainlab@gmail.com
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02130
- Recruiting
- VA Boston Healthcare System - Jamaica Plain Campus
-
Contact:
- Kathy Xie, PhD
- Phone Number: 8573645429
- Email: ctcnbrainlab@gmail.com
-
Contact:
- Katherine W Turk, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy older adults will show cognitive performance within 1.0 SD for age & education adjusted norms on a neuropsychological test battery
- Mild cognitive impairment (MCI) participants will show performance on delayed recall or one more or more other cognitive domains worse than 1.5 SD for age & education adjusted norms, an MMSE score between 25-30, and a MoCA score between 20-30.
Exclusion Criteria:
- Participants without a computer, smart phone and internet access will be excluded
- If they cannot understand the informed consent form or have moderate dementia.
- Mood disorders (e.g., PTSD, depression, anxiety) or alcohol and drug use that either interferes with day-to-day life or required hospitalization within the past 5 years
- Cerebrovascular disease
- Any medical condition whose severity could significantly impair cognition (e.g., stroke, frontotermporal dementia, Parkinson's disease) are exclusionary
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Mindfulness
MBSR course of mindfulness using focused attention, body scan practice and light chair yoga.
|
The Mindfulness Intervention is an adapted form of Mindfulness-based stress reduction (MBSR) training virtual class that meets for 10 weeks.
The class involves mindfulness training using awareness and focused attention, group discussion of the experience, and mindful movement.
The Mindfulness Intervention also includes daily home practice using mindfulness recordings.
Other Names:
Participants in this arm will first wait 10 weeks and then complete a mindfulness course with outcome measures assessed at baseline, after 10 weeks wait list and then after mindfulness course.
|
|
No Intervention: Mindfulness Waitlist
Individuals in the Mindfulness Waitlist group will not engage in any of the study interventions until 2 months has passed.
Then they will be enrolled in the Mindfulness Intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neuropsychological tests
Time Frame: From before the intervention (baseline) to after the intervention (post-intervention 10 weeks)
|
Paper-and-pencil tests measuring attention, processing speed, and memory.
|
From before the intervention (baseline) to after the intervention (post-intervention 10 weeks)
|
|
Performance on computerized tasks
Time Frame: From before the intervention (baseline) to after the intervention (post-intervention 10 weeks)
|
Reaction time and accuracy on computer tasks measuring attention and memory
|
From before the intervention (baseline) to after the intervention (post-intervention 10 weeks)
|
|
Resting state and event-related electrophysiology
Time Frame: From before the intervention (baseline) to after the intervention (post-intervention 10 weeks)
|
Electrophysiology measured while at rest and time-locked to performance on a computerized task measuring attention and memory
|
From before the intervention (baseline) to after the intervention (post-intervention 10 weeks)
|
|
Brain function and structure
Time Frame: From before the intervention (baseline) to after the intervention (post-intervention 10 weeks))
|
Blood-oxygen-level-dependent (BOLD) for functional magnetic resonance imaging.
Voxel-based morphometry (VBM) and diffusion tensor imaging (DTI) for structural magnetic resonance imaging.
|
From before the intervention (baseline) to after the intervention (post-intervention 10 weeks))
|
|
Survey outcomes
Time Frame: From before the intervention (baseline) to after the intervention (post-intervention 10 weeks))
|
Surveys measuring mood, social isolation, sleep, and quality of life
|
From before the intervention (baseline) to after the intervention (post-intervention 10 weeks))
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Wounds and Injuries
- Neurocognitive Disorders
- Cognition Disorders
- Dementia
- Tauopathies
- Neurodegenerative Diseases
- Craniocerebral Trauma
- Trauma, Nervous System
- Brain Injuries, Traumatic
- Cognitive Dysfunction
- Alzheimer Disease
- Brain Injuries
Other Study ID Numbers
- 1796795
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.